Low density parasitaemia, red blood cell polymorphisms and Plasmodium falciparum specific immune responses in a low endemic area in northern Tanzania. by Shekalaghe, Seif et al.
Shekalaghe, S; Alifrangis, M; Mwanziva, C; Enevold, A; Mwakalinga,
S; Mkali, H; Kavishe, R; Manjurano, A; Sauerwein, R; Drakeley, C;
Bousema, T (2009) Low density parasitaemia, red blood cell poly-
morphisms and Plasmodium falciparum specific immune responses in
a low endemic area in northern Tanzania. BMC Infectious Diseases,
9. ISSN 1471-2334
Downloaded from: http://researchonline.lshtm.ac.uk/5141/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
BioMed Central
Page 1 of 7
(page number not for citation purposes)
BMC Infectious Diseases
Open AccessResearch article
Low density parasitaemia, red blood cell polymorphisms and 
Plasmodium falciparum specific immune responses in a low endemic 
area in northern Tanzania
Seif Shekalaghe1,2, Michael Alifrangis3, Charles Mwanziva2, Anders Enevold3, 
Steve Mwakalinga3, Humphrey Mkali2, Reginald Kavishe2, 
Alphaxard Manjurano4, Robert Sauerwein1, Chris Drakeley4 and 
Teun Bousema*1
Address: 1Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 2Kilimanjaro 
Christian Medical College, Moshi, Tanzania, 3Centre for Medical Parasitology at the Department of International Health, Immunology and 
Microbiology, University of Copenhagen, and at the Department of infectious Diseases, Copenhagen University Hospital (Rigshospitalet), 
Copenhagen, Denmark and 4Joint Malaria Programme, Moshi, Tanzania; Kilimanjaro Christian Medical Centre, Moshi, Tanzania; Department of 
Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
Email: Seif Shekalaghe - sshekalaghe@yahoo.com; Michael Alifrangis - alifrangis@cmp.dk; Charles Mwanziva - cmwanziva@yahoo.com; 
Anders Enevold - enevold@cmp.dk; Steve Mwakalinga - smwakalinga@yahoo.com; Humphrey Mkali - junioraph@yahoo.com; 
Reginald Kavishe - rekavishe@yahoo.com; Alphaxard Manjurano - amanjurano@yahoo.co.uk; Robert Sauerwein - r.sauerwein@mmb.umcn.nl; 
Chris Drakeley - chris.drakeley@lshtm.ac.uk; Teun Bousema* - jt_bousema@yahoo.co.uk
* Corresponding author    
Abstract
Background: Low density Plasmodium falciparum infections, below the microscopic detection limit, may play an
important role in maintaining malaria transmission in low endemic areas as well as contribute to the maintenance
of acquired immunity. Little is known about factors influencing the occurrence of sub-microscopic parasitaemia
or the relation with immune responses.
We investigated possible associations between the occurrence of sub-microscopic P. falciparum parasite carriage
and antibody responses to the asexual stage antigens, G6PD deficiency and α+-thalassaemia in 464 subjects from
a low endemic area in northern Tanzania.
Methods: We used samples collected from two cross sectional surveys conducted during dry and wet season in
2005. Submicroscopic parasitaemia was detected by using quantitative nucleic acid sequence based amplification
(QT-NASBA). Genotyping for G6PD and α+-thalassaemia were performed by high throughput PCR; the
prevalence and level of total IgG antibodies against MSP-1, MSP-2 and AMA-1 were determined by ELISA.
Results: Compared to parasite free individuals, individuals carrying sub-microscopic densities of P. falciparum
parasites had significantly higher median antibody levels to MSP-1 (p = 0.042) and MSP-2 (p = 0.034) but not to
AMA-1 (p = 0.14) while no clear relation between sub-microscopic parasite carriage and G6PD deficiency or α+-
thalassaemia was observed.
Conclusion: Our data suggest a role for sub-microscopic parasite densities in eliciting or maintaining humoral
immune responses without evidence for a modulating effect of G6PD deficiency or α+-thalassaemia.
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Background
Plasmodium falciparum is responsible for the majority of
malaria attributed deaths in sub-Saharan Africa although
the parasites are also frequently present in the human cir-
culation without causing malaria symptoms. Individuals
in malaria-endemic areas can carry microscopically
detectable levels of P. falciparum asymptomatically[1,2].
Moreover, recent molecular detection techniques have
suggested the presence of a much greater proportion of
asymptomatic infections below the microscopic threshold
than previously believed [3,4]. Sub-microscopic infec-
tions have been primarily studied in areas of low and sea-
sonal malaria transmission [3-6]. Here, it has been shown
that sub-microscopic infections can persist for several
months [3,5], produce gametocytes [5] and, despite low
gametocyte concentrations in the infected individual,
contribute to the transmission of malaria to mosquitoes
[7-9]. Sub-microscopic infections may therefore play a
role in maintaining malaria transmission in areas of low
malaria endemicity. Despite their potential importance,
little is known about factors influencing the occurrence of
sub-microscopic parasitaemia and whether their presence
may be associated with protective immune responses.
However, long-term asymptomatic carriage of parasites at
microscopic densities has been associated with protective
immunity against subsequent clinical malaria attacks
[10,11]. Despite indications from an experimental study
showing that exposure to ultra low-dose infections may
elicit protective immunity [12], there have been no field
studies confirming the capacity of sub-microscopic infec-
tions to elicit or maintain immune responses.
Microscopically detected parasite carriage has been associ-
ated with several red blood cell polymorphisms, such as
α+-thalassaemia, sickle cell trait and glucose 6 phosphate
dehydrogenase (G6PD) deficiency [13,14]. In α+-thalas-
saemia, one gene of the two α-globin genes on each chro-
mosome 16 is deleted and the deficiency has been
associated with protection against severe [15,16] and mild
malaria [16,17]. G6PD deficiency is a common chromo-
some x-linked red blood cell enzymopathy with several
polymorphisms arisen from mutations in the G6PD gene.
In Africa, a single point-mutation leads to the variant
G6PD A with almost identical enzyme activity as the nor-
mal type (G6PD B), and a second point-mutation leads to
the G6PD A- variant with highly reduced enzyme activity
[18]. Similar to α+-thalassaemia, G6PD deficiency has
been associated with protection against severe [19,20] and
mild malaria [18,19,21]. Both α+-thalassaemia [22] and
G6PD deficiency [23] may also protect against asympto-
matic carriage of microscopically detectable levels of par-
asites although other studies did not find such
associations [24,25]. The effect of red blood cell polymor-
phisms on sub-microscopic parasite carriage is unknown.
Since these polymorphisms may not protect against initial
infection but rather result in a slower parasite growth rate,
as a consequence of a reduced parasite multiplication [26]
or increased clearance of infected red blood cells [27], we
hypothesize that the prevalence of sub-microscopic para-
site carriage is higher in α+-thalassaemic and G6PD defi-
cient individuals while that of high density parasitaemia
is reduced.
Here, we investigate for possible associations between
sub-microscopic P. falciparum parasite carriage, red blood
cell polymorphisms and antibody responses to the asex-
ual stage antigens that were recently explored as indicators
of exposure to parasite antigen[28]: Merozoite Surface
Protein (MSP)-1, MSP-2 and Apical Membrane Antigen
(AMA)-1. The study was conducted in a population in
northern Tanzania where the vast majority of parasite car-
riage occurs below the microscopic threshold for detec-
tion [4].
Methods
Study site and survey design
We utilized samples collected from a previously pub-
lished study [4]. Briefly, two all age cross-sectional surveys
were conducted during the dry and wet seasons (April and
August, respectively) in 2005 in the villages Msitu wa
Tembo, Kiruani and Magadini in the Lower Moshi area of
northern Tanzania (latitude 3°33'-3°44's; longitude
37°17'-37°24'E). The area is characterised by low malaria
transmission intensity with an entomologic inoculation
rate of ~2.3 infectious bites per person per year (95% CI
0.7–9.9) [29]. A previous study estimated a malaria inci-
dence in the study area of 38.4 episodes per 1000 person-
years at risk [29]. Participants were selected using village
census lists that were created for this study and computer
randomized tables. Individuals were individually selected
and invited to a central point in the village for sampling.
No individuals provided more than one sample (i.e. both
in the wet and dry season survey). In 2005, there was very
low rainfall and we observed no marked seasonality or
differences between the two cross-sectional surveys in par-
asite carriage [4]. Therefore we combined the data from
both surveys. The study protocol was approved by the eth-
ical committees of both the Tanzanian National Institute
of Medical Research (NIMR/HQ/Vol.IX/343) and the
London School of Hygiene & Tropical Medicine.
Data collection, sample processing and analysis
A questionnaire was used to collect information on demo-
graphic, anthropometric and general health indicators. A
single EDTA blood sample of approximately 200 μL was
obtained from each participant by finger prick. This sam-
ple was used for i) preparation of blood smears for micro-
scopy; ii) nucleic acid extraction for PCR and quantitative
nucleic acid sequence based amplification (QT-NASBA);
iii) plasma collection for immunological assays. Out of
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the total of 2752 individuals surveyed, 464 individuals
were randomly selected using computer randomized
tables from three age strata (below 5, 5–15 and above 15
years) in the ratio 1:1:1. No individuals were recruited
more than once. From these individuals, nucleic acids
were extracted from a 50 μL blood sample as described by
Boom et al. [30]. The first part of the extraction was done
in the field following the original guanidine isothiocy-
anate (GuSCN) RNA extraction method [30] until the
nucleic acids were bound to silica dioxide particles. The
remainder of the extraction was completed in the labora-
tory and RNA/DNA samples were stored at -20°C until
analysis. QT-NASBA parasite detection was performed as
described elsewhere using NucliSens Basic kits for ampli-
fication [31]. The forward primer was 5'-GTCATCTTTC-
GAGGTGACTT-3' (nucleotides 1136 to 1155); the reverse
primer was 5'-AATTCTAATACGACTCACTATAGGGA-
GAAGGAACTTTCTCGCTTGCGCGAA-3' (T7 promoter
sequence, linker, and nucleotides 1216 to 1235); the
Pf18S molecular beacon was 5'-6-carboxyfluorescein-
CGATCGGAGAAATCAAAGTCTTTGGG-CGATCG-
dimethylaminoazosulfonic acid-3' (molecular beacon
stem of 6 paired nucleotides and nucleotides 1182 to
1201). The time to positivity, i.e., the time point during
amplification at which the number of target amplicons
detected became higher than the mean for three negative
controls plus 20 standard deviations, was calculated [32].
The detection limit of the QT-NASBA is 20 parasites/mL
and parasite concentrations in test samples were deter-
mined using a standard ring stage parasite dilution series
that was included in each run [32].
Genotyping for G6PD deficiency was performed by
screening human DNA for single nucleotide polymor-
phisms in the G6PD gene (G202A) by a simple high
throughput method using PCR followed by detection
using sequence specific oligonucleotide probes (SSOPs)
and ELISA based technology [33]. Individuals with no
G202A mutation were classified G6PD B, heterozygotes
for the G202A mutation were classified G6PD A and
homozygote or hemizygote (males) for the G202A muta-
tion were classified G6PD A-. The prevalence of α+-thalas-
saemia was determined by detection of the African α-
globin deletion, α3.7, by PCR as described by Liu et al.
[34].
ELISA for the MSP-1, MSP-2 and AMA-1
IgG antibodies against blood stage malaria antigens were
detected by indirect ELISA, as previously described [28]
using recombinant MSP-119 (Wellcome genotype); MSP-2
(3D7), AMA-1 (3D7), which were produced as described
previously [35,36]. Briefly, flat bottom 96-well plates
[Immulon 4HBX, Thermo] were coated overnight with 50
μL of 0.5 mg/mL dilution of the specific antigen. After
washing with PBS-0.05% Tween [(PBS-T), 200 μL of
blocking buffer (1% skimmed milk in PBS-T) was added
for 3 hours at room temperature. After washing, plasma
samples were added in duplicate at a single dilution of 1/
1000 and incubated at 4°C overnight. 100 μL/well of rab-
bit anti-human IgG HRP Conjugate (1/5000) [Dako, Ely,
UK] was added and incubated for 1 hour at room temper-
ature. Plates were developed with o-phenyline-diamine
[Sigma]-H2O2 and the reaction was stopped with 50 μL
H2SO4. Plates were read at 490 nm. To generate an optical
density (OD) cut-off value above which samples were
deemed antibody positive, the distribution of OD values
was fitted as the sum of two Gaussian distributions
(assuming a narrow distribution of seronegatives and a
broader distribution of seropositives) using maximum
likelihood methods [37]. The mean OD of the Gaussian
corresponding to the seronegative population plus three
standard deviations was used as the cut-off for seropositiv-
ity. The normalised optical density in the different ELISA
assays was considered as an indicator of the magnitude of
antibody response in the analyses.
Statistical analysis
Statistical analysis of data was performed using SPSS (ver-
sion 14.0). Categorical variables were compared between
groups by the Pearson Chi-square test or Fisher's Exact
test. For non normally distributed numerical variables,
the non-parametric Mann-Whitney rank sum test or
Kruskal-Wallis H-test was used and the Interquartile range
(IQR) was used to describe the spread around the median.
For red blood cell polymorphisms, homozygotes and het-
erozygotes were separately compared with normal geno-
type as reference group. Multiple logistic and linear
regression models were used to adjust estimates for poten-
tial confounders.
Results
As previously reported for this population [4], parasite
prevalence was similar in the dry and wet seasons (April
and August, respectively), by microscopy (p = 0.49) and
QT-NASBA (p = 0.10). Microscopic parasite prevalence
and QT-NASBA parasite prevalence were not significantly
related to age (table 1) [4]. Since all participants of the sur-
vey were derived from the general population and were
apparently healthy, all parasite carriage can be considered
to be asymptomatic. Our data indicate that 90.0% (135/
150) of the asymptomatic parasite carriage occurs below
the microscopic threshold for parasite detection. Only P.
falciparum parasites were detected. Because there was no
obvious seasonality or age dependency in parasite car-
riage, data from both cross sectional surveys were com-
bined.
In total, 100.0% (464/464) and 95.9% (445/464) of the
samples were successfully genotyped for G6PD and α+-
thalassaemia status, respectively. The frequency of G6PD
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deficiency was 9.7% (45/464; G6PD A heterozygotes) and
3.7% (17/464; G6PD A-homozygous/hemizygous). Of
the G6PD A-individuals, 88.2% (15/17) were male,
11.8% (2/17) females. The frequency of α+-thalassaemia
was 24.3% (108/445; αα/α- heterozygotes) and 3.6%
(16/445; α-/α- homozygotes). Genotype polymorphisms
were equally distributed among different age strata men-
tioned above (p = 0.80 and p = 0.71 for G6PD and α+-tha-
lassaemia, respectively).
Red blood cell polymorphisms and P. falciparum parasite 
carriage
Parasite prevalence detectable by microscopy was low and
not related to red blood cell polymorphisms (table 2). The
prevalence of parasitaemia by 18S QT-NASBA was much
higher than that by microscopy, as previously described
[4], but also showed no statistically significant association
with either α+-thalassaemia or G6PD deficiency (table 2).
Sub-microscopic parasite carriage and P. falciparum 
specific immune responses
To compare the antibody response between sub-micro-
scopic parasite carriers and parasite free individuals, we
restricted our analyses to samples that had QT-NASBA
results and excluded individuals who had microscopically
detectable levels of asexual parasites (n = 14) and whose
numbers did not allow separate analysis. As shown in
table 3, the levels of antibodies to MSP-1 and MSP-2 were
significantly higher for sub-microscopic parasitemic indi-
viduals compared to parasite-free individuals (p = 0.042
and p = 0.034, respectively), while the sero-prevalence of
IgG antibodies to MSP-1 and MSP-2 was not significantly
different between the groups (p = 0.086 and p = 0.33,
respectively). For AMA-1 there was no statistically signifi-
cant difference in prevalence or level of IgG antibody
responses between sub-microscopic parasite carriers and
parasite free individuals (p = 0.14). None of these associ-
ations were confounded by α+-thalassaemia or G6PD sta-
tus.
Based on questionnaire data, we found no evidence of dif-
ferences in recent symptomatic infections between para-
site free and sub-microscopic parasite carriers. Between
these groups, there was no statistically significant differ-
ence in self-reported illness (p = 0.74), antibiotic use (p =
0.73) or antimalarial use (p = 0.66) in the two weeks prior
to sampling. In addition, body temperature at the
moment of sampling was not different between sub-
microscopic carriers and parasite-free individuals (p =
0.62).
Discussion
In this cross sectional study, we investigated the possible
relationship between sub-microscopic parasite carriage
red blood cell polymorphisms, and malaria specific
immune responses in an area of low malaria transmission
intensity. Our main findings are that individuals carrying
P. falciparum parasite densities below the microscopic
Table 1: The prevalence of P. falciparum infection by microscopy and QT-NASBA in relation to age
Parasite prevalence, % (n/N) <5 years 5–15 years >15 years P-value
Microscopy, prevalence (n/N) 1.8 (11/608) 2.4 (18/744) 1.6 (22/1369) 0.42
Microscopy (selection)* 1.5 (2/137) 5.1 (8/156) 3.1 (5/160) 0.21
QT-NASBA 27.0 (37/137) 36.5 (57/156) 33.1 (53/160) 0.22
*Selection = only those individuals who also had valid QT-NASBA results. For eleven samples included in the QT-NASBA, no information on age 
was available.
Table 2: The prevalence of P. falciparum infection and the frequency of G6PD and α+-thalassaemia variants
P. falciparum parasite prevalence as detected by
Microscopy QT-NASBA
G6PD, % (n/N)
B 3.0 (11/366) 32.2 (118/366)
A 6.7 (3/45) 35.6 (16/45)
A- 0.0 (0/16) 37.5 (6/16)
α+ – thalassaemia, % (n/N)
αα/αα 3.7 (11/295) 30.5 (90/295)
αα/α- 2.0 (2/100) 40.0 (40/100)¶
α-/α- 0.0 (0/14) 14.3 (2/14)
G6PD B and α-thalassaemia αα/αα served as a reference group for the comparisons. ¶p = 0.08 when compared to α+-thalassaemia αα/αα. Only 
samples were included in this table that had results for both QT-NASBA and microscopy
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detection limit (i.e. < 5 parasites/μL) had higher levels of
IgG antibody response to asexual stage antigens MSP-1
and MSP-2 compared to parasite free individuals.
Parasite densities will fluctuate over time in chronic infec-
tions [38] and it is therefore possible that sub-microscopic
parasite carriers had high density infections in the weeks
or months prior to sampling. We nevertheless consider it
unlikely that recent exposure to microscopically detecta-
ble levels of parasites can explain our findings. We did not
find evidence for a higher occurrence of recent sympto-
matic infections in sub-microscopic parasite carriers and
we consider asymptomatic high density infections
unlikely in our study area of low endemicity where micro-
scopically detectable infections in all age groups com-
monly result in symptomatic malaria and clinic
attendance [29]. In addition, our study was conducted in
a period when malaria transmission was extremely low as
a consequence of prolonged drought [4], making recent
(super-) infections unlikely. It has been previously
reported that sub-microscopic parasite densities can
remain at very low densities for several months [38] and
therefore it is probable that the observed increased
immune responses against blood stage parasites are the
result of chronic sub-microscopic infections. The phe-
nomenon that individuals with concurrent microscopic
parasitaemia have higher antibody responses is well doc-
umented [39] but it is an important observation that this
is also the case for sub-microscopic parasite densities. This
suggests that low dose blood stage infections are capable
of eliciting or maintaining humoral immune responses, as
was previously shown for protective cell mediated
immune responses [12]. Although our data are in line
with a recently published hypothesis that low density
infections contribute to sustained protection from
malaria in various intervention studies conducted in areas
of moderate to high transmission intensity [40], caution is
needed when speculating about protective immunity.
Asymptomatic chronic carriage of microscopically
detected parasites has been associated with the induction
of immune responses that may reduce the risk or rate of
re-infection, parasite density, incidence of clinical malaria
and severity of disease [10,11] but such a relation has
never been studied with low density sub-microscopic
infections. In our study area of low endemicity, it is likely
that chronic infections are composed of one or a few
clones and may therefore be poorly protective against
infection with genetically distinct parasite strains [38].
Future longitudinal studies should confirm the immune
boosting capacity of sub-microscopic parasite densities
that we observe and determine if chronic infections at
sub-microscopic densities are related to protective immu-
nity.
This is the first report on the relationship between red
blood cell polymorphisms and sub-microscopic parasi-
taemia. We hypothesized that the initial infection rates
would be similar for different genotypes, while the time to
reach densities that cause symptomatic malaria would be
longer for G6PD deficient individuals [41] and individu-
als with α+-thalassaemia. Based on this hypothesis, we
expected a higher prevalence of sub-microscopic parasite
carriage in G6PD deficient and α+-thalassaemic individu-
als and a lower microscopic parasite carriage. Our data do
not support this hypothesis. The number of individuals
with microscopic levels of parasites was too small to allow
any conclusions on a relation between asymptomatic
microscopic parasite carriage and G6PD and α+-thalassae-
mia. Thus, sub-microscopic parasite carriage appears
unrelated to G6PD deficiency or α+-thalassaemia.
Conclusion
In summary, our data suggest a role for sub-microscopic
parasite densities in eliciting or maintaining humoral
Table 3: P. falciparum specific immune responses in parasite free individuals and individuals with sub-microscopic parasite densities by 
18S QT-NASBA
Parasite free individuals Sub-microscopic parasite carriers p-value
MSP-1 IgG antibodies
prevalence, % (n/N) 68.0 (183/269) 76.7 (89/116) 0.086
median level (IQR) 0.26 (0.14 – 0.79) 0.33 (0.18 – 1.17) 0.042
MSP-2 IgG antibodies
prevalence, % (n/N) 53.4 (134/251) 58.9 (66/112) 0.33
median level (IQR) 0.32 (0.13 – 0.59) 0.41 (0.19 – 0.72) 0.034
AMA-1 IgG antibodies
prevalence, % (n/N) 61.0 (153/251) 65.2 (73/122) 0.44
median level (IQR) 0.34 (0.17 – 0.99) 0.48 (0.21 – 1.04) 0.14
Parasitaemia was detected by 18S QT-NASBA and microscopically confirmed parasite carriers were excluded from this table. The optical density in 
the ELISA was used as indicator of antibody level. P-values are obtained by χ2-test for antibody prevalence or Wilcoxon Rank-sum test for antibody 
level. The cut-off values for sero-positivity (antibody prevalence) for MSP-1, MSP-2 and AMA-1 were 0.171, 0.292 and 0.252, respectively.
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immune responses without evidence for a modulating
effect of G6PD deficiency or α+-thalassaemia. Longitudi-
nal studies are required to determine the extent in which
sub-microscopic parasites can generate (protective)
immune responses. Ideally, these studies should include
functional assays.
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